Kazia Therapeutics organizacji Rok IPO
Jaka jest wartość Rok IPO organizacji Kazia Therapeutics?
Wartość Rok IPO organizacji Kazia Therapeutics Limited to 1994
Jaka jest definicja Rok IPO?
Pierwsza oferta publiczna jest rodzajem oferty publicznej, w której akcje spółki zazwyczaj sprzedawane są inwestorom instytucjonalnym, którzy z kolei sprzedają się ogółowi społeczeństwa, na giełdzie papierów wartościowych, po raz pierwszy.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
Rok IPO firm w Health Care sektor na ASX w porównaniu do Kazia Therapeutics
Czym się zajmuję organizacja Kazia Therapeutics?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Firmy z rok ipo podobne do Kazia Therapeutics
- Wartość Rok IPO organizacji Sinopec Shanghai Petrochemical Co to 1993
- Wartość Rok IPO organizacji Delaware Investments Minnesota Municipal Income Fund II Inc to 1993
- Wartość Rok IPO organizacji Delaware Investments Colorado Insured Municipal Income Fund Inc to 1993
- Wartość Rok IPO organizacji Western Asset Municipal Partners Fund Inc to 1993
- Wartość Rok IPO organizacji Nuveen Maryland Quality Municipal Income Fund to 1993
- Wartość Rok IPO organizacji Enel Americas SA to 1993
- Wartość Rok IPO organizacji Kazia Therapeutics to 1994
- Wartość Rok IPO organizacji Hanover Insurance Inc to 1995
- Wartość Rok IPO organizacji Atlanticus Corp to 1995
- Wartość Rok IPO organizacji Integra Lifesciences Corp to 1995
- Wartość Rok IPO organizacji Telkom Indonesia (Persero) Tbk PT to 1995
- Wartość Rok IPO organizacji Myriad Genetics to 1995
- Wartość Rok IPO organizacji Redwood Trust to 1995